Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System

Scott Dryden-Peterson; Andy Kim; Mary-Ruth Joyce; Jennifer A Johnson; Arthur Y Kim; Lindsey R Baden; Ann E Woolley

doi:10.1093/ofid/ofac565

Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System

Open Forum Infect Dis. 2022 Oct 27;9(11):ofac565. doi: 10.1093/ofid/ofac565. eCollection 2022 Nov.

Authors

Scott Dryden-Peterson^{1

2

3

4

5}, Andy Kim^{1

6

5}, Mary-Ruth Joyce¹, Jennifer A Johnson^{1

5}, Arthur Y Kim^{6

5}, Lindsey R Baden^{1

5}, Ann E Woolley^{1

5}

Affiliations

¹ Brigham and Women's Hospital, Boston, Massachusetts, USA.
² Dana Farber Cancer Institute, Boston, Massachusetts, USA.
³ Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
⁴ Botswana Harvard AIDS Institute, Gaborone, Botswana.
⁵ Harvard Medical School, Boston, Massachusetts, USA.
⁶ Massachusetts General Hospital, Boston, Massachusetts, USA.

Abstract

There are limited data for the clinical efficacy of bebtelovimab in preventing severe coronavirus disease 2019. Among outpatients unable to take nirmatrelvir-ritonavir at a large health system, 10 of 377 (2.7%) patients who received bebtelovimab and 17 of 377 (4.5%) matched untreated patients were hospitalized or died. The 43% observed risk reduction with bebtelovimab was not statistically significant (P = 0.14).

Keywords: SARS-CoV-2; bebtelovimab; COVID-19; monoclonal antibody; pandemic.

Abstract

Grants and funding